Estabrook Capital Management’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Estabrook Capital Management’s Portfolio SGMO Stock Details SGMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-14	Closed	-$44	–	408
2022 Q4	$44	Hold	14	–	–	﹤0.01%	420
2022 Q3	$69	Hold	14	–	–	﹤0.01%	418
2022 Q2	$58	Hold	14	–	–	﹤0.01%	422
2022 Q1	$81	Hold	14	–	–	﹤0.01%	413
2021 Q4	$105	Hold	14	–	–	﹤0.01%	440
2021 Q3	$126	Hold	14	–	–	﹤0.01%	315
2021 Q2	$168	Hold	14	–	–	﹤0.01%	313
2021 Q1	$175	Hold	14	–	–	﹤0.01%	318
2020 Q4	$218	Hold	14	–	–	﹤0.01%	327
2020 Q3	$132	Hold	14	–	–	﹤0.01%	318
2020 Q2	$125	Hold	14	–	–	﹤0.01%	332
2020 Q1	$89	Hold	14	–	–	﹤0.01%	332
2019 Q4	$117	Buy	+14	New	+$129	﹤0.01%	339

Other funds holding SGMO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RCMU

Rokos Capital Management (UK) London, United Kingdom $13.2B AUM 85.71% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Estabrook Capital Management's SGMO Position: Q1 2023 in Review

Estabrook Capital Management sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q1 2023, closing a stake of 14 shares — an estimated $44 sold.

Estabrook Capital Management first reported a position in SGMO in Q4 2019 and held it in 13 quarters. The position peaked at $218 in Q4 2020. 179 funds tracked by Wall St. Rank hold SGMO as of Q1 2023.

Estabrook Capital Management reported no remaining SANGAMO THERAPEUTICS INC position as of Q1 2023 after selling out during the quarter.
Estabrook Capital Management sold 14 SANGAMO THERAPEUTICS INC shares in Q1 2023, an estimated $44.
Estabrook Capital Management first reported a position in SANGAMO THERAPEUTICS INC in Q4 2019 and held it in 13 quarters.
Estabrook Capital Management's SANGAMO THERAPEUTICS INC position peaked at $218 in Q4 2020.
179 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q1 2023.

Based on Estabrook Capital Management's 13F filing for Q1 2023, filed 12 May 2023.